ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Soluble erythropoietin receptor levels associate with inflammatory mediators but not with disease activity or cumulative organ damage in patients with systemic lupus erythematosus

Permanent link
https://hdl.handle.net/10037/15311
DOI
https://doi.org/10.1177/2058739218811032
Thumbnail
View/Open
article.pdf (175.2Kb)
Publisher`s version (PDF)
Date
2018-11-14
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Jones, Heather; Raymond, Warren David; Eilertsen, Gro Østli; Nossent, Johannes
Abstract
The erythropoietin receptor (EpoR) stimulates erythrocyte proliferation after erythropoietin binding. EpoR belongs to the cytokine receptor superfamily and can be found on macrophages and endothelial cells. As there are no data on the role of EpoR systemic autoimmune diseases, we investigated the role of soluble EpoR (sEpoR) in patients with systemic lupus erythematosus (SLE). In a cross-sectional study we recorded clinical characteristics, disease activity (SLEDAI-2K) and organ damage (SDI). sEpoR, autoantibodies and cytokines were measured by enzyme-linked immunosorbent assay (ELISA) in SLE patients (n=100) and compared with a rheumatoid arthritis (RA) cohort (n=57) and a cohort with noninflammatory back pain (NIBP; n=89). Data were analysed with non-parametric techniques. We found no significant difference in sEpoR levels across the SLE, RA and NIBP groups and sEpoR levels were similar in patients with (6% of SLE and 31% of RA) or without anaemia. sEpoR levels were unrelated to haemoglobin levels, SLEDAI-2K or SDI scores, but in both cohorts correlated with levels for C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor (TNF) and IL-1 (all P<0.001). sEpoR levels are not involved in anaemia or erythropoietin resistance in SLE and RA patients, but closely mirror the underlying inflammatory process. This suggests that increased shedding of sEpoR during inflammation occurs at other sites than bone marrow.
Description
Source at https://doi.org/10.1177/2058739218811032.
Publisher
SAGE Publications
Citation
Jones, H., Raymond, W., Eilertsen, G. & Nossent, J. (2018). Soluble erythropoietin receptor levels associate with inflammatory mediators but not with disease activity or cumulative organ damage in patients with systemic lupus erythematosus. European Journal of Rheumatology and Inflammation, 16. https://doi.org/10.1177/2058739218811032
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)